Background Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine
(RPV) is currently used as maintenance treatment for human immunodeficiency virus type 1 …

Introduction The treatment of HIV infection has been revolutionized in recent years thanks to
the advent of dual antiretroviral regimens, administered orally or as long-acting injectable …

Current Opinion in HIV and AIDS Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Background This study aimed to investigate factors contributing to non-sustained viral
suppression, including intermittent viremia and persistent low-level viremia, during …

The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated
by the lack of consensus on the threshold to consider. Building on real-world therapeutic …

Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical
trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine …

Objective Large inter-individual variability in the pharmacokinetics of rilpivirine and
cabotegravir has been reported in the first weeks after starting long-acting injectable (LAI) …

Current high-genetic-barrier regimens (either boosted PI-or second-generation integrase
inhibitor-based options), allow long-term control of HIV replication in people living with HIV …

Background Real-world data showing the long-term effectiveness of long-acting injectable
cabotegravir and rilpivirine are scarce. We assessed the effectiveness of cabotegravir and …

Background The aim of the study was to evaluate the 12-month cumulative probability of
treatment discontinuation (TD) in people with human immunodeficiency virus (HIV; PWH) …